RxDoctor Payments Data

Marc Sullivan, MD

Family Medicine · Fountain Hills, AZNPI 1437350030

Payments from drug & device makers

$5,527in general payments, 2019–2025

Across 344 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$692
  • Takeda Pharmaceuticals U.S.A., Inc.$480
  • AstraZeneca$452
  • Novo Nordisk$386
  • Novartis$343
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,513100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,527 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$216,830
Medicare patients
420
Services billed
2,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide194$265,374
EliquisApixaban78$82,133
MounjaroTirzepatide44$72,294
Repatha SureclickEvolocumab64$65,810
FarxigaDapagliflozin Propanediol44$53,869
JardianceEmpagliflozin27$43,316
Repatha SyringeEvolocumab48$36,075
ProliaDenosumab20$34,324
TrulicityDulaglutide29$33,744
TrintellixVortioxetine Hydrobromide30$23,680
RybelsusSemaglutide11$23,643
Praluent PenAlirocumab26$16,638
Rosuvastatin Calcium1,043$14,654
Ezetimibe506$11,542
EdarbiAzilsartan Medoxomil23$9,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$386$289,017205 claims
Lilly USA, LLCMounjaro, Trulicity$178$106,03873 claims
PfizerEliquis$92$82,13378 claims
AstraZenecaFarxiga$452$53,86944 claims
Boehringer IngelheimJardiance$53$43,31627 claims
AmgenProlia$692$34,32420 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$480$23,68030 claims
Arbor Pharmaceuticals, Inc.Edarbi$171$9,96623 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$4,445608 claims
AbbVieSynthroid$1,273$2,61449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Fountain Hills

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →